Wasim Sardar Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wasim Sardar Khan has a total of 270 co-authors. Here are the top co-authors by number of shared publications:
- Tim Hardingham
Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, UK
12 shared publications Kendrick To
University of Cambridge, Division of Trauma and Orthopaedic Surgery, Cambridge, UNITED KINGDOM
8 shared publications- Umile Giuseppe Longo
Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Rome, Italy
7 shared publications Christopher Mak
5 shared publications- K. T. Matthew Seah
Department of Orthopaedics, University of British Columbia, Vancouver, British Columbia, Canada; Warwick Clinical Trials Unit, University of Warwick, Coventry, United Kingdom
5 shared publications - Victor Lu
Chinese University of Hong Kong, Hong Kong, China
5 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by BMJ in BMJ Open Sport & Exercise Medicine
- Vol. 12 (4) , e003274
Genetic susceptibility to anterior cruciate ligament rupture in females: a systematic review of female-stratified candidate-gene evidence and the absence of genome-wide studies
- 1 October 2026
- Published by BMJ in BMJ Open Sport & Exercise Medicine
- Vol. 12 (4) , e003274
Open AccessGenetic susceptibility to anterior cruciate ligament rupture in females: a systematic review of female-stratified candidate-gene evidence and the absence of genome-wide studies
- Open Access
- 20 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5582
A Comparison of the Properties of Mesenchymal Stem Cells Derived from Different Synovial Sources: A Systematic Review
Mesenchymal stem cells (MSCs) are capable of self-renewal and differentiation into different cellular lineages, including adipocytes, chondrocytes, and osteocytes. This makes them strong candidates for repairing degenerative joint conditions such as osteoarthritis, in which native cartilage lacks repair capacity. The synovium is an attractive MSC source, with synovial MSCs demonstrating superior chondrogenic and proliferative potential compared to those from bone marrow or adipose tissue. The synovial joint is a heterogeneous environment, and MSCs can be isolated from the membrane, fluid, different histological subtypes of fibrous and adipose synovium, and different anatomical regions of synovium. This systematic review assesses whether MSCs from different synovial sources possess distinct properties. 2312 papers were identified, of which 10 met the inclusion and exclusion criteria and were included in the final review. Significant differences were identified in proliferation characteristics, immunophenotype and differentiation potential. Proximity to vasculature appeared to correlate with proliferation and differentiation potential, and MSCs from the synovial membrane may have superior proliferative characteristics compared to those from synovial fluid. More work is required to fully characterise these differences and understand their underlying molecular bases, but these findings may help inform the choice of MSC source for regenerative therapies.
- 20 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5582
Open AccessA Comparison of the Properties of Mesenchymal Stem Cells Derived from Different Synovial Sources: A Systematic Review
Mesenchymal stem cells (MSCs) are capable of self-renewal and differentiation into different cellular lineages, including adipocytes, chondrocytes, and osteocytes. This makes them strong candidates for repairing degenerative joint conditions such as osteoarthritis, in which native cartilage lacks repair capacity. The synovium is an attractive MSC source, with synovial MSCs demonstrating superior chondrogenic and proliferative potential compared to those from bone marrow or adipose tissue. The synovial joint is a heterogeneous environment, and MSCs can be isolated from the membrane, fluid, different histological subtypes of fibrous and adipose synovium, and different anatomical regions of synovium. This systematic review assesses whether MSCs from different synovial sources possess distinct properties. 2312 papers were identified, of which 10 met the inclusion and exclusion criteria and were included in the final review. Significant differences were identified in proliferation characteristics, immunophenotype and differentiation potential. Proximity to vasculature appeared to correlate with proliferation and differentiation potential, and MSCs from the synovial membrane may have superior proliferative characteristics compared to those from synovial fluid. More work is required to fully characterise these differences and understand their underlying molecular bases, but these findings may help inform the choice of MSC source for regenerative therapies.
- Open Access
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9330
Adipocyte-Derived Stem Cells in the Treatment of Spinal Cord Injuries in Animal Models: A Systematic Review
Spinal cord injury (SCI) represents a burdensome and currently incurable condition which affects over 20 million patients globally. Adipocyte-derived mesenchymal stem cell (ADSC) therapy may constitute a valuable strategy in treating this condition, owing to their unique cellular characteristics and beneficial effects on functional recovery. This PRISMA (Preferred Reporting Items for Systematic Reviews) review aims to assess whether ADSC therapy is a viable strategy for treating SCI in animal models. We identified a total of 1561 studies after performing a search of four databases, including PubMed, Web of Science, Scopus and Medline. After applying inclusion and exclusion criteria, we identified a total of 16 articles that were reviewed, assessed and reported in our study. General characteristics of these studies, results of stem cell characterisation, SCI induction protocols, locomotor recovery and bladder function following SCI, were investigated as part of our analysis. Fifteen studies suggested that ADSC therapy has a beneficial effect on motor recovery following SCI. The evidence base regarding adjuvant therapies was, however, variable. Further investigations into the mechanisms that underly recovery following ADSC therapy, and potential adjuvants which could enhance these effects, should follow the outcomes of this systematic review. In turn, this would help expand the treatment options available to SCI patients.
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9330
Open AccessAdipocyte-Derived Stem Cells in the Treatment of Spinal Cord Injuries in Animal Models: A Systematic Review
Spinal cord injury (SCI) represents a burdensome and currently incurable condition which affects over 20 million patients globally. Adipocyte-derived mesenchymal stem cell (ADSC) therapy may constitute a valuable strategy in treating this condition, owing to their unique cellular characteristics and beneficial effects on functional recovery. This PRISMA (Preferred Reporting Items for Systematic Reviews) review aims to assess whether ADSC therapy is a viable strategy for treating SCI in animal models. We identified a total of 1561 studies after performing a search of four databases, including PubMed, Web of Science, Scopus and Medline. After applying inclusion and exclusion criteria, we identified a total of 16 articles that were reviewed, assessed and reported in our study. General characteristics of these studies, results of stem cell characterisation, SCI induction protocols, locomotor recovery and bladder function following SCI, were investigated as part of our analysis. Fifteen studies suggested that ADSC therapy has a beneficial effect on motor recovery following SCI. The evidence base regarding adjuvant therapies was, however, variable. Further investigations into the mechanisms that underly recovery following ADSC therapy, and potential adjuvants which could enhance these effects, should follow the outcomes of this systematic review. In turn, this would help expand the treatment options available to SCI patients.
- Open Access
- 19 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13585
The Effects of Gender on Mesenchymal Stromal Cell (MSC) Proliferation and Differentiation In Vitro: A Systematic Review
Mesenchymal stromal cells (MSCs) have the potential for novel treatments of several musculoskeletal conditions due to their ability to differentiate into several cell lineages including chondrocytes, adipocytes and osteocytes. Researchers are exploring whether this could be utilized for novel therapies for joint afflictions. The role of gender in the ability of MSCs to differentiate and proliferate into different cells has not been clearly defined. This systematic review aims to report the current literature on studies, characterized by high quality and in-depth analysis even though quantitatively limited, that have looked at the role of gender in the differentiation and proliferation of MSCs. Sixteen studies were identified during the literature search, reporting 533 patients, of which 202 were male and 331 were female. MSC proliferation, phenotypic analysis and differentiation are reported and contrasted in terms of donor gender. Heterogeneity in methodologies across studies likely contributes to the inconclusive findings presented here, with no discernible statistical disparity observed between genders in differentiation traits. Nevertheless, the proliferation results indicate a notable gender-related impact. Future investigations should aim to ascertain the potential influence of gender on MSC proliferation capacities more conclusively, emphasizing the necessity of standardized protocols for MSC analyses to enhance accuracy and comparability across studies.
- 19 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13585
Open AccessThe Effects of Gender on Mesenchymal Stromal Cell (MSC) Proliferation and Differentiation In Vitro: A Systematic Review
Mesenchymal stromal cells (MSCs) have the potential for novel treatments of several musculoskeletal conditions due to their ability to differentiate into several cell lineages including chondrocytes, adipocytes and osteocytes. Researchers are exploring whether this could be utilized for novel therapies for joint afflictions. The role of gender in the ability of MSCs to differentiate and proliferate into different cells has not been clearly defined. This systematic review aims to report the current literature on studies, characterized by high quality and in-depth analysis even though quantitatively limited, that have looked at the role of gender in the differentiation and proliferation of MSCs. Sixteen studies were identified during the literature search, reporting 533 patients, of which 202 were male and 331 were female. MSC proliferation, phenotypic analysis and differentiation are reported and contrasted in terms of donor gender. Heterogeneity in methodologies across studies likely contributes to the inconclusive findings presented here, with no discernible statistical disparity observed between genders in differentiation traits. Nevertheless, the proliferation results indicate a notable gender-related impact. Future investigations should aim to ascertain the potential influence of gender on MSC proliferation capacities more conclusively, emphasizing the necessity of standardized protocols for MSC analyses to enhance accuracy and comparability across studies.
- Open Access
- 27 June 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (7) , 656
Mesenchymal Stromal Cells for the Enhancement of Surgical Flexor Tendon Repair in Animal Models: A Systematic Review and Meta-Analysis
Flexor tendon lacerations are primarily treated by surgical repair. Limited intrinsic healing ability means the repair site can remain weak. Furthermore, adhesion formation may reduce range of motion post-operatively. Mesenchymal stromal cells (MSCs) have been trialled for repair and regeneration of multiple musculoskeletal structures. Our goal was to determine the efficacy of MSCs in enhancing the biomechanical properties of surgically repaired flexor tendons. A PRISMA systematic review was conducted using four databases (PubMed, Ovid, Web of Science, and CINAHL) to identify studies using MSCs to augment surgical repair of flexor tendon injuries in animals compared to surgical repair alone. Nine studies were included, which investigated either bone marrow- or adipose-derived MSCs. Results of biomechanical testing were extracted and meta-analyses were performed regarding the maximum load, friction and properties relating to viscoelastic behaviour. There was no significant difference in maximum load at final follow-up. However, friction, a surrogate measure of adhesions, was significantly reduced following the application of MSCs (p = 0.04). Other properties showed variable results and dissipation of the therapeutic benefits of MSCs over time. In conclusion, MSCs reduce adhesion formation following tendon injury. This may result from their immunomodulatory function, dampening the inflammatory response. However, this may come at the cost of favourable healing which will restore the tendon’s viscoelastic properties. The short duration of some improvements may reflect MSCs’ limited survival or poor retention. Further investigation is needed to clarify the effect of MSC therapy and optimise its duration of action.
- 27 June 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (7) , 656
Open AccessMesenchymal Stromal Cells for the Enhancement of Surgical Flexor Tendon Repair in Animal Models: A Systematic Review and Meta-Analysis
Flexor tendon lacerations are primarily treated by surgical repair. Limited intrinsic healing ability means the repair site can remain weak. Furthermore, adhesion formation may reduce range of motion post-operatively. Mesenchymal stromal cells (MSCs) have been trialled for repair and regeneration of multiple musculoskeletal structures. Our goal was to determine the efficacy of MSCs in enhancing the biomechanical properties of surgically repaired flexor tendons. A PRISMA systematic review was conducted using four databases (PubMed, Ovid, Web of Science, and CINAHL) to identify studies using MSCs to augment surgical repair of flexor tendon injuries in animals compared to surgical repair alone. Nine studies were included, which investigated either bone marrow- or adipose-derived MSCs. Results of biomechanical testing were extracted and meta-analyses were performed regarding the maximum load, friction and properties relating to viscoelastic behaviour. There was no significant difference in maximum load at final follow-up. However, friction, a surrogate measure of adhesions, was significantly reduced following the application of MSCs (p = 0.04). Other properties showed variable results and dissipation of the therapeutic benefits of MSCs over time. In conclusion, MSCs reduce adhesion formation following tendon injury. This may result from their immunomodulatory function, dampening the inflammatory response. However, this may come at the cost of favourable healing which will restore the tendon’s viscoelastic properties. The short duration of some improvements may reflect MSCs’ limited survival or poor retention. Further investigation is needed to clarify the effect of MSC therapy and optimise its duration of action.
- Open Access
- 26 April 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 16 (4) , 324-333
Adipose-derived regenerative therapies for the treatment of knee osteoarthritis
Knee osteoarthritis is a degenerative condition with a significant disease burden and no disease-modifying therapy. Definitive treatment ultimately requires joint replacement. Therapies capable of regenerating cartilage could significantly reduce financial and clinical costs. The regenerative potential of mesenchymal stromal cells (MSCs) has been extensively studied in the context of knee osteoarthritis. This has yielded promising results in human studies, and is likely a product of immunomodulatory and chondroprotective biomolecules produced by MSCs in response to inflammation. Adipose-derived MSCs (ASCs) are becoming increasingly popular owing to their relative ease of isolation and high proliferative capacity. Stromal vascular fraction (SVF) and micro-fragmented adipose tissue (MFAT) are produced by the enzymatic and mechanical disruption of adipose tissue, respectively. This avoids expansion of isolated ASCs ex vivo and their composition of heterogeneous cell populations, including immune cells, may potentiate the reparative function of ASCs. In this editorial, we comment on a multicenter randomized trial regarding the efficacy of MFAT in treating knee osteoarthritis. We discuss the study’s findings in the context of emerging evidence regarding adipose-derived regenerative therapies. An underlying mechanism of action of ASCs is proposed while drawing important distinctions between the properties of isolated ASCs, SVF, and MFAT.
- 26 April 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 16 (4) , 324-333
Open AccessAdipose-derived regenerative therapies for the treatment of knee osteoarthritis
Knee osteoarthritis is a degenerative condition with a significant disease burden and no disease-modifying therapy. Definitive treatment ultimately requires joint replacement. Therapies capable of regenerating cartilage could significantly reduce financial and clinical costs. The regenerative potential of mesenchymal stromal cells (MSCs) has been extensively studied in the context of knee osteoarthritis. This has yielded promising results in human studies, and is likely a product of immunomodulatory and chondroprotective biomolecules produced by MSCs in response to inflammation. Adipose-derived MSCs (ASCs) are becoming increasingly popular owing to their relative ease of isolation and high proliferative capacity. Stromal vascular fraction (SVF) and micro-fragmented adipose tissue (MFAT) are produced by the enzymatic and mechanical disruption of adipose tissue, respectively. This avoids expansion of isolated ASCs ex vivo and their composition of heterogeneous cell populations, including immune cells, may potentiate the reparative function of ASCs. In this editorial, we comment on a multicenter randomized trial regarding the efficacy of MFAT in treating knee osteoarthritis. We discuss the study’s findings in the context of emerging evidence regarding adipose-derived regenerative therapies. An underlying mechanism of action of ASCs is proposed while drawing important distinctions between the properties of isolated ASCs, SVF, and MFAT.
- Open Access
- 23 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15494
The Effects of Chronological Age on the Chondrogenic Potential of Mesenchymal Stromal Cells: A Systematic Review
Tissue engineering and cell therapy for regenerative medicine have great potential to treat chronic disorders. In musculoskeletal disorders, mesenchymal stromal cells (MSCs) have been identified as a relevant cell type in cell and regenerative strategies due to their multi-lineage potential, although this is likely to be a result of their trophic and immunomodulatory effects on other cells. This PRISMA systematic review aims to assess whether the age of the patient influences the chondrogenic potential of MSCs in regenerative therapy. We identified a total of 3027 studies after performing a search of four databases, including Cochrane, Web of Science, Medline, and PubMed. After applying inclusion and exclusion criteria, a total of 14 papers were identified that were reviewed, assessed, and reported. Cell surface characterization and proliferation, as well as the osteogenic, adipogenic, and chondrogenic differentiation, were investigated as part of the analysis of these studies. Most included studies suggest a clear link between aged donor MSCs and diminished clonogenic and proliferative potential. Our study reveals a heterogeneous and conflicting range of outcomes concerning the chondrogenic, osteogenic, and adipogenic potential of MSCs in relation to age. Further investigations on the in vitro effects of chronological age on the chondrogenic potential of MSCs should follow the outcomes of this systematic review, shedding more light on this complex relationship.
- 23 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15494
Open AccessThe Effects of Chronological Age on the Chondrogenic Potential of Mesenchymal Stromal Cells: A Systematic Review
Tissue engineering and cell therapy for regenerative medicine have great potential to treat chronic disorders. In musculoskeletal disorders, mesenchymal stromal cells (MSCs) have been identified as a relevant cell type in cell and regenerative strategies due to their multi-lineage potential, although this is likely to be a result of their trophic and immunomodulatory effects on other cells. This PRISMA systematic review aims to assess whether the age of the patient influences the chondrogenic potential of MSCs in regenerative therapy. We identified a total of 3027 studies after performing a search of four databases, including Cochrane, Web of Science, Medline, and PubMed. After applying inclusion and exclusion criteria, a total of 14 papers were identified that were reviewed, assessed, and reported. Cell surface characterization and proliferation, as well as the osteogenic, adipogenic, and chondrogenic differentiation, were investigated as part of the analysis of these studies. Most included studies suggest a clear link between aged donor MSCs and diminished clonogenic and proliferative potential. Our study reveals a heterogeneous and conflicting range of outcomes concerning the chondrogenic, osteogenic, and adipogenic potential of MSCs in relation to age. Further investigations on the in vitro effects of chronological age on the chondrogenic potential of MSCs should follow the outcomes of this systematic review, shedding more light on this complex relationship.
- Open Access
- 6 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3227
Bone Marrow-Derived Mesenchymal Stem Cell Implants for the Treatment of Focal Chondral Defects of the Knee in Animal Models: A Systematic Review and Meta-Analysis
Osteoarthritis remains an unfortunate long-term consequence of focal cartilage defects of the knee. Associated with functional loss and pain, it has necessitated the exploration of new therapies to regenerate cartilage before significant deterioration and subsequent joint replacement take place. Recent studies have investigated a multitude of mesenchymal stem cell (MSC) sources and polymer scaffold compositions. It is uncertain how different combinations affect the extent of integration of native and implant cartilage and the quality of new cartilage formed. Implants seeded with bone marrow-derived MSCs (BMSCs) have demonstrated promising results in restoring these defects, largely through in vitro and animal studies. A PRISMA systematic review and meta-analysis was conducted using five databases (PubMed, MEDLINE, EMBASE, Web of Science, and CINAHL) to identify studies using BMSC-seeded implants in animal models of focal cartilage defects of the knee. Quantitative results from the histological assessment of integration quality were extracted. Repair cartilage morphology and staining characteristics were also recorded. Meta-analysis demonstrated that high-quality integration was achieved, exceeding that of cell-free comparators and control groups. This was associated with repair tissue morphology and staining properties which resembled those of native cartilage. Subgroup analysis showed better integration outcomes for studies using poly-glycolic acid-based scaffolds. In conclusion, BMSC-seeded implants represent promising strategies for the advancement of focal cartilage defect repair. While a greater number of studies treating human patients is necessary to realize the full clinical potential of BMSC therapy, high-quality integration scores suggest that these implants could generate repair cartilage of substantial longevity.
- 6 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3227
Open AccessBone Marrow-Derived Mesenchymal Stem Cell Implants for the Treatment of Focal Chondral Defects of the Knee in Animal Models: A Systematic Review and Meta-Analysis
Osteoarthritis remains an unfortunate long-term consequence of focal cartilage defects of the knee. Associated with functional loss and pain, it has necessitated the exploration of new therapies to regenerate cartilage before significant deterioration and subsequent joint replacement take place. Recent studies have investigated a multitude of mesenchymal stem cell (MSC) sources and polymer scaffold compositions. It is uncertain how different combinations affect the extent of integration of native and implant cartilage and the quality of new cartilage formed. Implants seeded with bone marrow-derived MSCs (BMSCs) have demonstrated promising results in restoring these defects, largely through in vitro and animal studies. A PRISMA systematic review and meta-analysis was conducted using five databases (PubMed, MEDLINE, EMBASE, Web of Science, and CINAHL) to identify studies using BMSC-seeded implants in animal models of focal cartilage defects of the knee. Quantitative results from the histological assessment of integration quality were extracted. Repair cartilage morphology and staining characteristics were also recorded. Meta-analysis demonstrated that high-quality integration was achieved, exceeding that of cell-free comparators and control groups. This was associated with repair tissue morphology and staining properties which resembled those of native cartilage. Subgroup analysis showed better integration outcomes for studies using poly-glycolic acid-based scaffolds. In conclusion, BMSC-seeded implants represent promising strategies for the advancement of focal cartilage defect repair. While a greater number of studies treating human patients is necessary to realize the full clinical potential of BMSC therapy, high-quality integration scores suggest that these implants could generate repair cartilage of substantial longevity.
- Open Access
- 2 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (23) , 15210
Evaluating the Effect of Hypoxia on Human Adult Mesenchymal Stromal Cell Chondrogenesis In Vitro: A Systematic Review
Human adult mesenchymal stromal cells (MSCs) from a variety of sources may be used to repair defects in articular cartilage by inducing them into chondrogenic differentiation. The conditions in which optimal chondrogenic differentiation takes place are an area of interest in the field of tissue engineering. Chondrocytes exist in vivo in a normally hypoxic environment and thus it has been suggested that exposing MSCs to hypoxia may also contribute to a beneficial effect on their differentiation. There are two main stages in which MSCs can be exposed to hypoxia, the expansion phase when cells are cultured, and the differentiation phase when cells are induced with a chondrogenic medium. This systematic review sought to explore the effect of hypoxia at these two stages on human adult MSC chondrogenesis in vitro. A literature search was performed on PubMed, EMBASE, Medline via Ovid, and Cochrane, and 24 studies were ultimately included. The majority of these studies showed that hypoxia during the expansion phase or the differentiation phase enhances at least some markers of chondrogenic differentiation in adult MSCs. These results were not always demonstrated at the protein level and there were also conflicting reports. Studies evaluating continuous exposure to hypoxia during the expansion and differentiation phases also had mixed results. These inconsistent results can be explained by the heterogeneity of studies, including factors such as different sources of MSCs used, donor variability, level of hypoxia used in each study, time exposed to hypoxia, and differences in culture methodology.
- 2 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (23) , 15210
Open AccessEvaluating the Effect of Hypoxia on Human Adult Mesenchymal Stromal Cell Chondrogenesis In Vitro: A Systematic Review
Human adult mesenchymal stromal cells (MSCs) from a variety of sources may be used to repair defects in articular cartilage by inducing them into chondrogenic differentiation. The conditions in which optimal chondrogenic differentiation takes place are an area of interest in the field of tissue engineering. Chondrocytes exist in vivo in a normally hypoxic environment and thus it has been suggested that exposing MSCs to hypoxia may also contribute to a beneficial effect on their differentiation. There are two main stages in which MSCs can be exposed to hypoxia, the expansion phase when cells are cultured, and the differentiation phase when cells are induced with a chondrogenic medium. This systematic review sought to explore the effect of hypoxia at these two stages on human adult MSC chondrogenesis in vitro. A literature search was performed on PubMed, EMBASE, Medline via Ovid, and Cochrane, and 24 studies were ultimately included. The majority of these studies showed that hypoxia during the expansion phase or the differentiation phase enhances at least some markers of chondrogenic differentiation in adult MSCs. These results were not always demonstrated at the protein level and there were also conflicting reports. Studies evaluating continuous exposure to hypoxia during the expansion and differentiation phases also had mixed results. These inconsistent results can be explained by the heterogeneity of studies, including factors such as different sources of MSCs used, donor variability, level of hypoxia used in each study, time exposed to hypoxia, and differences in culture methodology.
- Open Access
- 18 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (10) , 2620
From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?
Complex immune response to infection has been highlighted, more than ever, during the COVID-19 pandemic. This review explores the immunomodulatory treatment of moderate-to-severe forms of this viral sepsis in the context of specific immunopathogenesis. Our objective is to analyze in detail the existing strategies for the use of immunomodulators in COVID-19. Immunomodulating therapy is very challenging; there are still underpowered or, in other ways, insufficient studies with inconclusive or conflicting results regarding a rationale for adding a second immunomodulatory drug to dexamethasone. Bearing in mind that a “cytokine storm” is not present in the majority of COVID-19 patients, it is to be expected that the path to the adequate choice of a second immunomodulatory drug is paved with uncertainty. Anakinra, a recombinant human IL-1 receptor antagonist, is a good choice in this setting. Yet, the latest update of the COVID-19 Treatment Guidelines Panel (31 May 2022) claims that there is insufficient evidence to recommend either for or against the use of anakinra for the treatment of COVID-19. EMA’s human medicines committee recommended extending the indication of anakinra to include treatment of COVID-19 in adult patients only recently (17 December 2021). It is obvious that this is still a work in progress, with few ongoing clinical trials. With over 6 million deaths from COVID-19, this is the right time to speed up this process. Our conclusion is that, during the course of COVID-19, the immune response is changing from the early phase to the late phase in individual patients, so immunomodulating therapy should be guided by individual responses at different time points.
- 18 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (10) , 2620
Open AccessFrom Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?
Complex immune response to infection has been highlighted, more than ever, during the COVID-19 pandemic. This review explores the immunomodulatory treatment of moderate-to-severe forms of this viral sepsis in the context of specific immunopathogenesis. Our objective is to analyze in detail the existing strategies for the use of immunomodulators in COVID-19. Immunomodulating therapy is very challenging; there are still underpowered or, in other ways, insufficient studies with inconclusive or conflicting results regarding a rationale for adding a second immunomodulatory drug to dexamethasone. Bearing in mind that a “cytokine storm” is not present in the majority of COVID-19 patients, it is to be expected that the path to the adequate choice of a second immunomodulatory drug is paved with uncertainty. Anakinra, a recombinant human IL-1 receptor antagonist, is a good choice in this setting. Yet, the latest update of the COVID-19 Treatment Guidelines Panel (31 May 2022) claims that there is insufficient evidence to recommend either for or against the use of anakinra for the treatment of COVID-19. EMA’s human medicines committee recommended extending the indication of anakinra to include treatment of COVID-19 in adult patients only recently (17 December 2021). It is obvious that this is still a work in progress, with few ongoing clinical trials. With over 6 million deaths from COVID-19, this is the right time to speed up this process. Our conclusion is that, during the course of COVID-19, the immune response is changing from the early phase to the late phase in individual patients, so immunomodulating therapy should be guided by individual responses at different time points.